Assessment of HER-2/neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas

Authors

  • L.G. Buchynska R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • O.V. Brieiev R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • N.P. Iurchenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-2.12973

Keywords:

CCNE1, copy number high subtype, endometrial cancer, HER-2/neu, с-MYC

Abstract

Summary. Aim: To analyze copy number variations of HER-2/neu, c-MYC and CCNE1 oncogenes and their protein expression in endometrioid endometrial carcinomas in relation to the degree of tumor progression and presence of a family history of cancer in cancer patients. Materials and Methods: The study was conducted on endometrial cancer (EC) samples from 68 patients with I–II FIGO stages of disease. Copy number analysis of HER-2/neu, c-MYC and CCNE1 genes was performed by quantitative PCR. Protein expression was analyzed using immunohistochemistry. Results: Assessment of copy number variations of HER-2/neu, c-MYC and CCNE1 genes revealed their amplification in the tumors of 18.8, 25.0 and 14.3% of EC patients, respectively. High expression of corresponding proteins was detected in 14.6, 23.5 and 65.6% of patients, respectively. It was established that HER-2/neu gene amplification is more common in the group of tumors of low differentiation grade than in moderate grade EC (35.7 and 5.5% of cases, respectively, < 0.05). Also, high expression of c-Myc protein was more frequently observed in low differentiated tumors compared to the moderately differentiated EC (36.6 and 13.2% of cases, respectively, p < 0.05). Expression of HER-2/neu and cyclin E proteins was found to be dependent on the depth of tumor invasion into the myometrium. High expression of HER-2/neu protein was observed in 25.0 and 4.1% of EC patients with tumor invasion > ½ and < ½ of the myometrium, respectively, and cyclin E — in 86.7 and 46.6% of cases, respectively, < 0.05. It was shown that among patients with a family history of cancer, a larger proportion of cases with high expression of c-Myc protein was observed compared to the group of patients with sporadic tumors (43.8 and 17.3%, respectively; < 0.05). Conclusions: Amplification of HER-2/neu gene, along with high expression of c-Myc, HER-2/neu and cyclin E proteins, are associated with such indices of tumor progression as a low differentiation grade and deep myometrial invasion, suggesting the potential possibility of including these markers in the panel for determining the molecular EC subtype associated with an aggressive course of the disease. In a certain category of EC patients, there is a relationship between a family history of cancer and high expression of c-Myc protein.

References

Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014; 15: e268–78.

The Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67–73.

Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 2018; 29: 1180–88.

Cosgrove CM, Tritchler DL, Cohn DE, et al. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 2018; 148: 174–80.

Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer — combined analysis of the PORTEC cohorts. Clin Cancer Res 2016; 22: 4215–24.

Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med 2014; 4. pii: a014241.

Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007; 26: 6469–87.

Minella AC, Rosner MR, Siu KT. An integrated view of cyclin E function and regulation. Cell Cycle 2012; 11: 57–64.

Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol 2015; 125: 89–98.

Cook LS, Nelson HE, Stidley CA, et al. Endometrial cancer and a family history of cancer. Gynecol Oncol 2013; 130: 334–9.

Bharati R, Jenkins MA, Lindor NM, et al. Does risk of endometrial cancer for women without a germline mutation in a DNA mismatch repair gene depend on family history of endometrial cancer or colorectal cancer? Gynecol Oncol 2014; 133: 287–92.

Buchynska LG, Brieieva OV, Iurchenko NP, et al. DNA damage in tumor cells and peripheral blood lymphocytes of endometrial cancer patients assessed by the comet assay. Exp Oncol 2017; 39: 299–303.

Buchynska LG, Brieieva OV, Nekrasov KA, Nespryadko SV. The study of mismatch repair in endometrial cancer patients with a family history of cancer. Exp Oncol 2015; 37: 272–6.

Buchynska LG, Brieieva OV. Sensitivity to 4-hydroxyestradiol and DNA repair efficiency in peripheral blood lymphocytes of endometrial cancer patients. Exp Oncol 2018; 40: 68–72.

Kurman RJ, Carcangiu ML, Herrington CS. World Health Organisation classification of tumours of the female reproductive organs. 4th Revised ed. International Agency for Research on Cancer, 2014. 316 p.

Senchenko VN, Liu J, Loginov W, et al. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 2004; 23: 5719–28.

Rudenko EE, Lapska YV, Gerashchenko GV, et al. Heterozygous deletions are main cause of expression alterations of PPM1M and PRICLE2 genes in human clear cell renal cell carcinomas. Biopolym Cell 2015; 31: 29–33.

Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract 2016; 3: 14.

Hussein YR, Broaddus R, Weigelt B, et al. The genomic heterogeneity of FIGO grade 3 endometrioid carcinoma impacts diagnostic accuracy and reproducibility. Int J Gynecol Pathol 2016; 35: 16–24.

Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015; 113: 299–310.

Riben MW, Malfetano JH, Nazeer T, et al. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Mod Pathol 1997; 10: 823–31.

Morrison C, Zanagnolo V, Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 2006; 24: 2376–85.

Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010; 116: 15–20.

Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med 2014; 138: 343–50.

Grushko TA, Filiaci VL, Mundt AJ, et al. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008; 108: 3–9.

Birkeland E, Krohn A, Trovik J, et al. C-MYC gene amplification in endometrial cancer is associated with aggressive tumors. Cancer Res 2011; 71: Abstract nr 331.

Raeder MB, Birkeland E, Trovik J, et al. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One 2013; 8: e54873.

Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 2009; 106: 4834–9.

Zhang Q, Xu P, Lu Y, Dou H. Correlation of MACC1/c-Myc expression in endometrial carcinoma with clinical/pathological features or prognosis. Med Sci Monit 2018; 24: 4738–44.

Nakayama K, Rahman MT, Rahman M, et al. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas. Int J Oncol 2016; 48: 506–16.

Noske A, Brandt S, Valtcheva N, et al. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer. Oncotarget 2017; 8: 14794–805.

Kuhn E, Bahadirli-Talbott A, Shih IM. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Mod Pathol 2014; 27: 1014–19.

El-Gerzawy AMS, Ansary MMSA, Hussein IL, et al. Study of Her-2/neu and TOP2A expression in familial versus sporadic breast carcinoma. Med Res J 2013; 12: 21–9.

Brożek I, Kardaś I, Ochman K, et al. HER2 amplification has no prognostic value in sporadic and hereditary ovarian tumours. Hered Cancer Clin Pract 2006; 4: 39–42.

Chappuis PO, Donato E, Goffin JR, et al. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 2005; 16: 735–42.

Zetner DB, Bisgaard ML. Familial colorectal cancer type X. Curr Genomics 2017; 18: 341–59.

Abdel-Rahman WM, Ollikainen M, Kariola R, et al. Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene 2005; 24: 1542–51.

Dominguez-Valentin M, Therkildsen C, Veerla S, et al. Distinct gene expression signatures in lynch syndrome and familial colorectal cancer type x. PLoS One 2013; 8: e71755.

Downloads

Published

05.06.2023

How to Cite

Buchynska, L., Brieiev, O., & Iurchenko, N. (2023). Assessment of HER-2/neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas. Experimental Oncology, 41(2), 138–143. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-2.12973

Issue

Section

Original contributions

Most read articles by the same author(s)